Letter to the editor: A reminder to screen for varices! Atezolizumab/bevacizumab for HCC

Affiliations

¹ Department of Internal MedicineDonald and Barbara Zucker School of Medicine at Hofstra/Northwell HealthManhassetNew YorkUSA.
² Department of Internal Medicine, Division of Hepatology, Sandra Atlas Bass Center for Liver Diseases & TransplantationDonald and Barbara Zucker School of Medicine at Hofstra/Northwell HealthManhassetNew YorkUSA.

Comment

Kelly Suchman et al. Hepatology. 2022 Oct.

. 2022 Oct;76(4):E78-E79.

doi: 10.1002/hep.32556. Epub 2022 May 20.

¹ Department of Internal MedicineDonald and Barbara Zucker School of Medicine at Hofstra/Northwell HealthManhassetNew YorkUSA.
² Department of Internal Medicine, Division of Hepatology, Sandra Atlas Bass Center for Liver Diseases & TransplantationDonald and Barbara Zucker School of Medicine at Hofstra/Northwell HealthManhassetNew YorkUSA.

No abstract available

Comment on

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Gaillard VE, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Personeni N, Pressiani T, Sharma R, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ. D'Alessio A, et al. Hepatology. 2022 Oct;76(4):1000-1012. doi: 10.1002/hep.32468. Epub 2022 Apr 8. Hepatology. 2022. PMID: 35313048 Free PMC article.

1. D’Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, Felden J, Schulze K, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study. Hepatology. 2022;76:1000–12.
1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T‐Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.
1. Genentech, Inc . Avastin: highlights of prescribing information; 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125085s332lbl.pdf
1. Greten TF, Mauda‐Havakuk M, Heinrich B, Korangy F, Wood BJ. Combined locoregional‐immunotherapy for liver cancer. J Hepatol. 2019;70(5):999–1007.